Verastem (VSTM): Not sure if placebo was part of the repo...

Reply Private New

Next 10 Prev Next

Send PM Follow Ignore

Followers	1
Posts	131
Boards Moderated	0
Alias Born	09/12/2017

MaineMan5

Re: 0whammies post# 222

Monday, 06/18/2018 9:39:52 AM

Monday, June 18, 2018 9:39:52 AM

Not sure if placebo was part of the reported testing but but they announced "statistically significant improvement" with a p-value of <.0001 which indicates extremely high confidence the drug works. In the link below are all the poster presentations and study details.

Title: The Efficacy of Duvelisib Monotherapy Following Disease Progression on Ofatumumab Monotherapy in Patients with Relapsed/Refractory CLL or SLL in a Phase 3 Crossover Extension Study
Lead author: Dr. Peter Hillman, St. James University Hospital, Leeds, UK
Final Abstract Code: PF354
Summary: In the previously reported Phase 3 DUO™ study oral duvelisib monotherapy achieved a statistically significant improvement in median progression-free survival (mPFS) compared to ofatumumab in patients with relapsed or refractory CLL/ SLL (13.3 months versus 9.9 months, respectively; HR=0.52; p<0.0001), along with a manageable safety profile (Flinn, ASH 2017).

http://www.verastem.com/media/publications/posters/